JPWO2022244876A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022244876A5 JPWO2022244876A5 JP2023522741A JP2023522741A JPWO2022244876A5 JP WO2022244876 A5 JPWO2022244876 A5 JP WO2022244876A5 JP 2023522741 A JP2023522741 A JP 2023522741A JP 2023522741 A JP2023522741 A JP 2023522741A JP WO2022244876 A5 JPWO2022244876 A5 JP WO2022244876A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- sequence
- seq
- cell receptor
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 16
- 108091008874 T cell receptors Proteins 0.000 claims 14
- 102100031059 Cancer/testis antigen 55 Human genes 0.000 claims 7
- 101000922015 Homo sapiens Cancer/testis antigen 55 Proteins 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 7
- 230000035772 mutation Effects 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 229940041181 antineoplastic drug Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 239000012650 DNA demethylating agent Substances 0.000 claims 1
- 229940045805 DNA demethylating agent Drugs 0.000 claims 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021085406 | 2021-05-20 | ||
| PCT/JP2022/020990 WO2022244876A1 (ja) | 2021-05-20 | 2022-05-20 | 抗腫瘍剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022244876A1 JPWO2022244876A1 (enrdf_load_stackoverflow) | 2022-11-24 |
| JPWO2022244876A5 true JPWO2022244876A5 (enrdf_load_stackoverflow) | 2025-04-17 |
Family
ID=84141709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023522741A Pending JPWO2022244876A1 (enrdf_load_stackoverflow) | 2021-05-20 | 2022-05-20 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPWO2022244876A1 (enrdf_load_stackoverflow) |
| WO (1) | WO2022244876A1 (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024163292A1 (en) * | 2023-01-30 | 2024-08-08 | Board Of Regents, The University Of Texas System | T-cell receptors targeting her2 and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5984113B2 (ja) * | 2012-06-11 | 2016-09-06 | 学校法人慶應義塾 | がん免疫療法 |
| US20210380657A1 (en) * | 2018-10-25 | 2021-12-09 | The Council Of The Queensland Institute Of Medical Research | T-Cell Receptors and Uses Thereof |
| EP3927727A1 (en) * | 2019-02-20 | 2021-12-29 | Fred Hutchinson Cancer Research Center | Binding proteins specific for ras neoantigens and uses thereof |
-
2022
- 2022-05-20 JP JP2023522741A patent/JPWO2022244876A1/ja active Pending
- 2022-05-20 WO PCT/JP2022/020990 patent/WO2022244876A1/ja active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220313795A1 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
| US20240408191A1 (en) | Nucleic acid vaccines | |
| JP6925688B2 (ja) | 水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン | |
| JP2023015151A (ja) | 呼吸器合胞体ウイルスワクチン | |
| JP2019506156A (ja) | Ｈｉｖ感染症のｒｎａ誘導型治療のための方法及び組成物 | |
| ES2545885T3 (es) | Eliminación de respuestas inmunitarias contra vectores virales | |
| KR20180096591A (ko) | 광범위 인플루엔자 바이러스 백신 | |
| JP2015522264A5 (enrdf_load_stackoverflow) | ||
| JP2012500001A5 (enrdf_load_stackoverflow) | ||
| CN101863971A (zh) | 转移素衍生物及其用途 | |
| US11273170B2 (en) | Methods of treating cancer | |
| JP2014529399A5 (enrdf_load_stackoverflow) | ||
| JPWO2022244876A5 (enrdf_load_stackoverflow) | ||
| US10988522B2 (en) | Proteolically resistant cyclotides with angiotensin 1-7 like activity | |
| RU2012146542A (ru) | Способ ингибирования репликации вич в клетках млекопитающих и у людей | |
| JP2020127419A5 (enrdf_load_stackoverflow) | ||
| WO2023215235A2 (en) | Peptide inhibitors for chromodomain helicase dna binding protein 4 (chd4) | |
| JPWO2020024915A5 (enrdf_load_stackoverflow) | ||
| WO2019017713A9 (ko) | AR 유전자 및 mTOR 유전자의 발현을 동시에 억제하는 핵산 | |
| CN101020710A (zh) | 一种整合酶抑制肽及其在艾滋病药物制备中的应用 | |
| JP2006504403A5 (enrdf_load_stackoverflow) | ||
| JP2009500314A5 (enrdf_load_stackoverflow) | ||
| Soros | Graduate Department of Molecular and Medical Genetics | |
| Soros | Modulation of HIV-1 Rev transport and function | |
| HK1237653A1 (zh) | 核酸疫苗 |